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REVIEW
DRUG TRIALS FOR TREATMENT OF HUMAN ANGIOSTRONGYLIASIS
Márcia Bohrer MENTZ(1) & Carlos GRAEFF-TEIXEIRA(2)
SUMMARY
Abdominal and cerebral angiostrongyliasis are two important infections produced by metastrongylid worms, the former occurring
in Central and South America and the later in Asia and Pacific Islands. Drug treatment is a challenge since the worms and its evolving
larvae live or migrate inside vessels and efficient killing of the parasites may produce more severe lesions. Larvicidal effect of certain
drugs appears to be more easily accomplished but this outcome is not useful in abdominal angiostrongyliasis since clinical manifestations
appear to result from sexual maturation of the worms. We review the drug trials in murine experimental models and conclude that
most of them could not be considered good candidates for treatment of human infection, except for PF1022A, pyrantel and flubendazole.
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INTRODUCTION
Human angiostrongyliasis has been widely reported from various
parts of the world. Among the food-borne zoonotic diseases,
Angiostrongylus cantonensis4, the causative agent of human eosinophilic
meningoencephalitis1, and Angiostrongylus costaricensis32, the causative
agent of human abdominal angiostrongyliasis have such a medical
importance that studies have been carried out in order to search for
suitable drugs. The trials of treatment have been done both on adults
and larvae stages.
It is known that drug efficacy is influenced by various factors
including route, dosage and regimen of the treatment. In addition, in the
treatment of diseases produced by tissue-dwelling parasites, allergenic
components of killed worms may cause adverse effects on the host7,8,17.
Therefore, effective treatment will be established after these factors are
taken into account through basic studies using experimental models.
CHEMOTHERAPY AFTER WORM MATURATION
Many studies have examined the effects of various
neuropharmacological agonists and antagonists on the motility of
nemathelmints, suggesting the existence of excitatory cholinergic and
inhibitory gabergic mechanisms.
Avermectin B1a, one of the parasitic macrocyclic lactones produced
by actinomycets of Streptomyces avermitilis, may act on the nervous
system of various nematodes as well as other animals including crustacea
and mammals, possibly through an effect on γ-amino-butyric acid
(GABA). It was also suggested that it could paralyze Angiostrongylus
cantonensis, through a neuropharmacological mechanism including
GABA and acetylcholine24,35.
SANO et al.36 developed an in vitro method to study the effects of
drugs on the motility of small helminths and observed the paralyzing
effects of avermectin B1a on Angiostrongylus cantonensis, using 3-6 X
10-18 mg. The drug caused a sustained inhibition in the motility, with a
relaxation of the parasite. ISHII et al.13 extended the in vitro studies to in
vivo experiments in rats. Avermectin B1a was given intraperitoneally
(ip) six weeks after infection, and a sustained paralysis of worm by this
drug was suggested from the following aspects: the change of the first
larval stage count in feces; histological observations of lung tissues of
the host and the reproductive system of female worms, and the motility
of recovered worms in vitro. When the drug was given per os (po), three
days after infection, a significant reduction in the recovery rate of worms
was observed.
ISHII et al.14 administered ivermectin ip to rats infected with
Angiostrongylus cantonensis. They observed a significant reduction in
the recovery of adult worms when the drug was given at 2 mg/kg 0.5 to
72 h and four weeks after infection, compared to the non-treated, infected
control group.
TERADA et al.49,50 searched the effects of some alkaloids on the
motility of some parasitic helminths, isolated frog rectus and mouse
ileum. They verified that tuberostomine (TS) at 6.7 X 10(-6) approximately
180
MENTZ, M.B. & GRAEFF-TEIXEIRA, C. - Drug trials for treatment of human angiostrongyliasis. Rev. Inst. Med. trop. S. Paulo, 45(4): 179-184, 2003.
2 X 10(-5), an alkaloid from Stemona japonica, abolished the motility of
A. cantonensis. With N-methylcystisine (N-MC) and matrine (Mat),
alkaloids from Sophora flavescens, the motility of A. cantonensis
musculature was affected spastically by N-Mc (1.2 X 10-6, approximately
1.2 X 10-4 M), and paralytically by Mat 10(-5), approximately 10(-4) M.
From the results on interactions between these alkaloids and known
neuropharmacological agents, it was suggested that the effects of both
alkaloids are elicited through a neuropharmacological mechanism in
parasitic helminths and host tissues.
TERADA et al.40 examined the effects of various cholinergic agents
on the motility of A. cantonensis to define their neuropharmacological
properties. It was suggested that the excitatory cholinergic mechanism
in this parasite was mediated through nicotinic receptors, and it was
basically similar to that reported in Ascaris suum. The same group
demonstrated spastic paralysis caused by pyrantel tartrate, another
gabergic anthelmintic, through direct stimulation of the nicotinic
cholinergic receptors in A. cantonensis 41.
TERADA et al.42 compared the paralysis of A. cantonensis produced
by avermectin B1a and ivermectin to that produced by phenylephrine
(an alpha-adrenergic agonist) and strychnine (a cholinergic inhibitor)
and concluded that a gabergic mechanism is involved in the paralyzing
action of both macrocyclic lactones.
The reproductive functions of A. cantonensis are apparently affected
by milbemycin D, another macrocyclic lactone derivate, through an
indirect mode of action including paralysis and inhibition in food intake
and energy and/or synthetic metabolism38. The in vitro motility of females
recovered from rats was inhibited, and almost all females and males
were semitransparent colourless. Results obtained from sectioned worms
showed little content in the digestive tract and uteri. In addition, there
were few eggs and first-stage larvae in the lung tissues of treated rats.
Inhibitory and stimulatory actions of milbemycin oxime on the motility
of A. cantonensis and Dirofilaria immitis are probably mediated through
gabergic and cholinergic mechanisms26. TERADA & SANO46 studied
the effects of santonin on the motility of A. cantonensis and some other
parasitic nematodes. Santonin paralyzed the worms at lower
concentrations (10- 9 – 10–7 M), whereas a slight stimulatory effect on
the motility was also seen at its higher concentrations (10-6 – 10-4 M).
The results suggested that santonin has inhibitory and stimulatory actions
through stimulating gabergic and cholinergic mechanism in the
parasite.
CUCKLER et al.5 conducted studies to determine whether
thiabendazole, a potent and broad-spectrum anthelmintic, would affect
Angiostrongylus cantonensis. They showed that this drug was highly
effective in controlling the early invasive stages of the rat lungworm.
Also depending upon the dosage, time, and duration of medication, the
worms were killed, their migration to the lungs was delayed and the
oviposition was prevented.
MORERA & BONTEMPO33 tested diethylcarbamazine (DEC),
thiabendazole and albendazole as treatment of cotton rats (Sigmodon
hispidus) infected with A. costaricensis, 40 days after infection. Several
trials were carried out, varying the dose and the timing of the treatment.
They demonstrated that the parasites were actively moving instead of
being killed and also that lesions were more severe after treatment.
TERADA & SANO47 examined the effects of diethylcarbamazine
(DEC) on the motility of adult A. cantonensis and Dirofilaria immitis.
They suggested that the DEC inhibitory and stimulatory action was
produced through the gabergic and cholinergic mechanisms in both adult
parasites. Other neuropharmacological agents, including eserine,
phenyllephrine and dibenamine, did not have any effect on the motility of
irradiated and non-irradiated Angiostrongylus cantonensis adult females15.
TERADA et al.45 compared in vitro effects of 19 anthelmintics on
the motility of A. costaricensis and A. cantonensis. Phenolic compounds
(hexylresorcinol, bithionol and niclosamide) and levamisole were all
effective on the motility of A. costaricensis, but other derivates having
piperazine (diethylcarbamazine and piperazine), lactone (santonin,
avermectin B1a and ivermectin) and benzimidazole (mebendazole and
thiabendazole) had no efficacy at all.
TERADA et al.51 did some preliminary trials on treatment after worm
maturation in abdominal angiostrongyliasis in mice, using mebendazole,
one of the effective antilarval drugs against nematodes, including A.
costaricensis. No definitive conclusion about killing efficacy was made
and several topics were suggested to be addressed in forthcoming studies,
like the influence of immune status of the host on the efficacy of the drug.
Mebendazole at 10 mg/kg nd with four intermittent doses of 5 mg/
kg given weekly led to a lowest worm recovery of A.costaricensis, in
groups treated with four daily successive doses, suggesting involvement
of different killing mechanisms. Otherwise, since the drug is not highly
effective to kill the worms, the inhibition of egg formation and/or
oviposition would be more desirable for treating abdominal
angiostrongyliasis after worm maturation54.
KACHI et al.18 examined the effects of PF1022A, a cyclodepsipeptide
isolated from a mycelial cake of Mycelia sterilia, on adult Angiostrongylus
cantonensis in the pulmonary arteries and larvae migrating into the central
nervous systems of rats, although the compound does not pass the blood-
brain barrier. The treatment killed especially female worms. This gender
selective effect would be attributable to non-neuropharmacological
mechanisms20.
CHEMOTHERAPY BEFORE WORM MATURATION
Considering the migration paths of developing larvae of
Angiostrongylus cantonensis in vertebrates and the probable association
of worm maturation and pathogenic changes caused by Angiostrongylus
costaricensis, it is important to test the efficacy of drugs on the early
stages of infection, with both nematodes.
HAYASHI et al.9 examined the effects of mebendazole against A.
cantonensis in rats. The drug was more effective in the larval stage (3rd and
4th stages) than in the adult stage. Reduction rates higher than 90% were
observed in groups treated with ≥ 3 mg/kg, that was similar to its clinical
dosis (3 -10 mg/kg) for human intestinal nematodes. When mebendazole
suspended in propylene glycol was given orally or intraperitoneally, no
difference in reduction rate was seen between two routes.
MAKI & YANAGISAWA28 compared the effects of flubendazole
and thiabendazole on the larvae of Angiostrongylus cantonensis and other
helminths. Thiabendazole had no larvicidal effect on A. cantonensis at
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the doses of 10 mg/kg/day for six consecutive days. On the other hand,
no larvae were found in the brain of the mice treated with flubendazole
at 5 mg/kg/day for six days. The same high efficacy of flubendazole (50
mg/kg po) was seen in mice with different worm burdens (50, 250 or
500 larvae of A. cantonensis) with almost complete larvicidal effect,
irrespective of the worm burden. The results also suggested that worm
density had an effect on the fecundity of this parasite29. This effect may
be due to fibrous changes in host lung tissues and not to changes in the
physiology of the worms. The density-dependent effects on fecundity
play a role in the population dynamics of both the parasite and host as
regulatory mechanisms in the field.
MAKI & YANAGISAWA30 gave flubendazole and mebendazole po
at 10 mg/kg/day 5-7 days post-infection (total 30 mg/kg), resulting in
93-100% reduction of A. cantonensis larvae in mice and rats. No
significant difference was observed between the effects of the two drugs.
It was possible to treat A. cantonensis adults in rats by administering
flubendazole or mebendazole at 10 mg/kg/day for 10 consecutive days.
The drugs exhibit better anthelmintic efficacy in a divided than in a
single dosis regimen.
ISHIH et al.16 obtained significant inhibition on egg development of
Angiostrongylus costaricensis in vitro caused by pyrantel (10(-9) – 10(-80)
g/ml) and levamisole (10(-9) – 10(-8) g/ml). None of the eggs developed to
first-stage larvae in higher concentrations of these anthelmintics
(10(-7)g/ml). Furthermore, incubation with these drugs at 10(-8)g/ml for at
least 3 h or at 10(-4)g/ml for 1 h caused irreversible effects on egg
development.
MAKI & YANAGISAWA31 determined the effect of flubendazole
po administered at 10 mg/kg/day for five consecutive days (the 11th; 20th
or 40th post-infection) on the number of first-stage larvae of
Angiostrongylus cantonensis, released in the faeces of rats. Faecal
examination for five months showed that L1 release ceased one week
after conclusion of treatment and resumed one to two months later in
86% of the rats.
In order to study the sensitivity of the developing larvae and adult of
A. cantonensis, flubendazole and mebendazole were administered at 10
mg/kg to rats 3 and 10 days post-infection and to those harbouring the
adult worms after 70 days post-infection. Almost all of the larvae were
eliminated from the rats medicated 3 days post-infection. The larvicidal
effects of the drugs administered 10 days post-infection were not so
high. On the other hand, when the drugs were administered 70 days
post-infection, no effects were seen on the number, body size and weight
of recovered worm and the release of L1, concluding that the developing
larvae were more sensitive to the drugs27.
KANDA & MAKI23 observed the in vitro egg release of A.
cantonensis from rats treated with flubendazole and demonstrated that
the drug, even at the single dose as low as 10 mg/kg, affected the
physiology of adult worms in rats. No direct evidence was obtained on
effects of flubendazole po administered to rats on eggs and the first-
stage larvae. The authors hypothesized that flubendazole might affect
the formation of fertilized eggs from early embrionated stages and/or
the release of the eggs from the worms immediately after the conclusion
of the treatment, leading to the reduction in the number of the L1. Testing
these hypothesis is worthy of further investigations.
KAMATH et al.22 observed the larvicidal effect of perbendazole given
po and subcutaneously to mice infected with A. cantonensis at different
stages of infection. The subcutaneous route of administration was more
effective than the oral one. They also showed the complete larvicidal
effect of the drug at early stages of infection.
KAMATH et al.21 verified that the combined therapy of levamisole
and flubendazole was 100% efficient against A. cantonensis infection in
mice. The drugs were evaluated on the 15th day post infection. Both
drugs given prior to experimental infection showed no prophylactic
activity.
The larvicidal effect of albendazole was studied in the experimental
infection with Angiostrongylus cantonensis in mice treated with dosages
of 5, 10 and 25 mg/kg/day beginning 5, 10 or 15 days post-infection,
respectively, for 7, 14 or 21 consecutive days. It was effective when
given within 15 days post-infection10.
Levamisole was another anthelmintic tested against larval stages of
A. cantonensis in rats and A. costaricensis in mice and the results
suggested that the drug had conspicuous in vivo effects against larval
stages of A. costaricensis as well as A. cantonensis12. ISHII11 also verified
the effects of levamisole on the first-stage larva of A. cantonensis and
suggested that levamisole affected the L1 output through a direct
paralyzing action on the worm and an indirect pathway through inhibition
of energy metabolism.
ISHII et al.14 administered ivermectin intraperitonially to rats infected
with Angiostrongylus cantonensis. When the drug was given at
2.0 mg/kg after 3 weeks post infection, a significant inhibition of the
first larval stage output in rat faeces was observed.
TERADA et al.39 examined the anti-larval effects of milbemycin D
on A. cantonensis in rats and mice and on A. costaricensis in mice.
Compared with non-treated control group, significant reductions in the
first stage larval counts in feces (LPG/female), number of recovered
worms, host lung-body weight ratio, body weight, and mortality were
seen in the groups receiving 10 successive daily doses of 5 mg/kg, both
in rats and mice. Some effect was also seen with five or 20 successive
doses. From these results, it was suggested that milbemicyn D had
conspicuous in vivo effects against larval stages in both nematodes.
PF1022A killed developing larvae of A. costaricensis after five
successive doses and it was well absorbed either po or by parenteral
administration43. This larvicidal activity was observed with any of the four
forms of PF1022A, although forms alpha and III were more efficient against
tissue-dwelling nematodes than the form I and form II when given po20.
CHEMOTHERAPY AND IMMUNE STATUS OF THE HOST
Great interest has been recently directed towards advances in
understanding the interactions between chemotherapeutic actions of anti-
parasitic drugs and immune status of the host. Most of the studies using
such approach have been carried out on anti-protozoan and anti-trematode
chemotherapy.
Immunosuppression may reduce the efficacy of treatment in
experimental hosts infected with several parasitosis, including
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schistosomiasis, malaria, trypanosomiasis, filariasis6 and
strongyloidiasis37. The enhancement of drug efficacy through
immunopotentiation was also demonstrated for some diseases caused
also by tissue parasites like schistosomiasis25 and visceral leishmaniasis2.
However, individual variability of the host’s immune response prevents
a clear control for demonstration of the drug effects.
The fungal metabolite cyclosporin A (CsA) has been used as a tool
of investigating cellular immune mechanisms in various parasitic
infections52. YOSHIMURA et al.55 tried to determine the possible effects
of cyclosporin A (CsA) on Angiostrongylus cantonensis infection and
eosinophilia in mice. The data indicated a direct damaging activity of
CsA against certain developmental stages of the parasite.
TERADA & SANO48 did trials to assess protective resistance against
reinfection with Angiostrongylus costaricensis in mice whose primary
infection was treated with milbemycin D, a larvicidal anthelmintic. The
protection was more remarkable in three situations: 1) when the larvicidal
treatment was done later; 2) with high inocula at the primary infection;
3) when the infection and larvicidal treatment was repeated. The
protective resistance lasted at least six months after primary infection.
TUNGTRONGCHITR et al.53 investigated the relation between
immunopotentiation and efficacy of mebendazole in sensitized mice
infected with adult A. costaricensis. A significant decrease in the
establishment of infection and in worm growth was probably the result
of development of a protective humoral immunity in the sensitized mice.
CONCLUSION
Although the many experimental studies on drug treatment of
Angiostrongylus sp. infections in mice and rats, many aspects are still
open to investigation before studies on human infection are carried out.
Several compounds have a significant larvicidal effect, what may be
specially useful in treating cerebral angiostrongyliasis. Otherwise, in
abdominal angiostrongyliasis, the most striking clinical manifestations
occur after worm maturation and there is also the concern about the
possibility of extended lesions secondary to parasite’s death inside blood
vessels. Longitudinal seroepidemiological studies are urgently required
to further clarify the natural history of human infection in both cerebral
and abdominal angiostrongyliasis. This knowledge is critical for future
phase II and III studies with candidate drugs.
RESUMO
Ensaios com drogas para o tratamento da
angiostrongilíase humana
Angiostrongilíase abdominal e cerebral são duas infecções
importantes produzidas por metastrongilídeos, a primeira delas ocorrendo
nas Américas Central e do Sul e a segunda, na Ásia e Ilhas do Pacífico.
O tratamento é complicado pelo fato das larvas e vermes adultos viverem
e migrarem dentro dos vasos sanguíneos, sendo que as lesões podem se
agravar com a morte desses parasitos. Os efeitos larvicidas de
determinadas drogas parecem ser mais eficazes, porém não são úteis no
tratamento em angiostrongilíase abdominal, onde as manifestações
clínicas podem resultar da maturidade sexual dos vermes. Este estudo
faz uma revisão das drogas utilizadas para o tratamento de ambas as
parasitoses, em modelos experimentais murinos, realizados antes e depois
da maturação dos vermes. A maioria das drogas testadas não pode ainda
ser considerada candidata a ensaios de tratamento em infecções humanas,
com exceção do PF1022A, pirantel e flubendazol.
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